Replies to post #5386 on Innovus Pharmaceuticals Inc. (fka INNV)

[ShawnP123]

You're the FU University. Your hype along with INNV hype has done nothing. You site numbers and come up with the fact they are holding off until March for the Q4.

There is no market confidence in INNV. Their continued dilution is killing them. It's the same approach Damaj took at Apricus. Don't forget before he left, the stock was going downhill. His tenure was short as CEO at Apricus. Makes you wonder if he bailed do to his miscalculations.

Your assessment of everything has been wrong when it comes to where the stock should be. You site revenues, but the dilution is killing the company.

How many shares outstanding do you think they will have when they report? I'm predicting around 140-150 which is almost double from when I first bought the stock. They are at a lower pps at this point. Forget about the revenues, it hasn't made a bit of difference and with continued dilution (which will happen), the stock won't do much at all.

The best thing that could happen at this time is for the stock to drop to 0.05 and possibly give people a chance to get back some of the money they have lost on this pig.

[s_Henderson]

This is a waiting game and the longer it drags on the more likely is a further drop in share price. But speculating about where this bottoms out or not is really superfluous as one guess is as good (or bad) as another.

What is for sure is that this period belongs to the voices of the pessimists. Don't let yourself upset by it. Once we get FDA approval all the good news we had in the past which had no noticable influence on the share price will then have a delayed effect.
It's really unfortunate that this stock has thus far hinged on FDA approval, but that's how the stock is perceived and I'm OK with that since approval is only a matter of WHEN, not IF. The absolute worst case scenario would be a CLR because of some formality issues.

I also find most points of critism about Dr. D unfounded. He is certainly not diluting this stock for poor reasons. He needs cash on hand in order to be able to commercialize FlutiCare and this has always been expected. Where else should he have gotten the required money from? This is after all still an early stage pharmaceutical company which just recently managed to become cashflow positive. I ask all the critics and armchair CEOs to make better suggestions instead of just screaming that Dr. D. is a poor businessman. That way you they would at least give some credibility to their statements. But this is usually when the critics get silent as any suggestion would reveal that they have no idea about how to run a business.

By the way, the market supports the view that the latest offering wasn't a bad business move. Otherwise we would have seen a sharp drop in share price and that absolutely didn't happen! If I hear the pessimists constantly say the same "the market is always right" then they should at least acknowledge that this time the market doesn't consider the latest S-1 a problem. The same goes for the premature issuance of the Novalere shares!

[Adrock]

Well what do you know?

New Lows!